OrthoPediatrics Corp. (KIDS)
NASDAQ$25.08
Market Cap
$609.11M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
665 of 924
Rank in Industry
84 of 118
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
KIDS Insider Trading Activity
KIDS Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $293,000 | 1 | 100 |
Related Transactions
| Gerritzen Daniel J | General Counsel and Secretary | 0 | $0 | 1 | $293,000 | $-293,000 |
About OrthoPediatrics Corp.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking …
Insider Activity of OrthoPediatrics Corp.
Over the last 12 months, insiders at OrthoPediatrics Corp. have bought $0 and sold $293,000 worth of OrthoPediatrics Corp. stock.
On average, over the past 5 years, insiders at OrthoPediatrics Corp. have bought $426,413 and sold $2.85M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,235 shares for transaction amount of $48,721 was made by Ruf Harold () on 2022‑06‑16.
List of Insider Buy and Sell Transactions, OrthoPediatrics Corp.
| 2024-08-21 | Sale | Gerritzen Daniel J | General Counsel and Secretary | 10,000 0.0385% | $29.30 | $293,000 | -19.07% | |
| 2024-03-11 | Sale | Bailey David R | President and CEO | 3,213 0.0137% | $27.59 | $88,647 | -1.77% | |
| 2024-03-11 | Sale | Throdahl Mark C | director | 2,433 0.0104% | $27.59 | $67,126 | -1.77% | |
| 2024-03-11 | Sale | Hite Fred | COO and CFO | 3,195 0.0136% | $27.59 | $88,150 | -1.77% | |
| 2024-03-11 | Sale | Odle Gregory A | President of Scoliosis | 2,768 0.0118% | $27.59 | $76,369 | -1.77% | |
| 2024-03-11 | Sale | Gerritzen Daniel J | General Counsel and Secretary | 2,741 0.0117% | $27.59 | $75,624 | -1.77% | |
| 2024-02-22 | Sale | Hauser Joseph W | Pres. Trauma & Def. Correction | 2,903 0.0123% | $28.06 | $81,458 | -2.77% | |
| 2023-08-11 | Sale | Schlotterback Terry D | director | 2,610 0.0111% | $38.25 | $99,833 | -22.03% | |
| 2023-06-26 | Sale | Hite Fred | COO and CFO | 4,356 0.0196% | $43.69 | $190,304 | -28.64% | |
| 2023-04-27 | Sale | Odle Gregory A | President of Scoliosis | 3,333 0.0146% | $50.10 | $166,969 | -37.83% | |
| 2023-04-25 | Sale | Odle Gregory A | President of Scoliosis | 828 0.0037% | $50.02 | $41,420 | -36.23% | |
| 2023-04-21 | Sale | Odle Gregory A | President of Scoliosis | 644 0.0029% | $50.02 | $32,212 | -35.61% | |
| 2023-03-06 | Sale | Throdahl Mark C | director | 4,515 0.0199% | $43.83 | $197,872 | -17.57% | |
| 2023-03-06 | Sale | Bailey David R | President and CEO | 4,052 0.0181% | $44.40 | $179,910 | -17.57% | |
| 2023-03-06 | Sale | Hite Fred | COO and CFO | 4,099 0.0181% | $43.77 | $179,397 | -17.57% | |
| 2023-03-06 | Sale | Odle Gregory A | Executive Vice President | 3,421 0.0152% | $44.03 | $150,618 | -17.57% | |
| 2023-03-06 | Sale | Gerritzen Daniel J | General Counsel and Secretary | 3,315 0.0149% | $44.62 | $147,916 | -17.57% | |
| 2023-03-02 | Sale | Hauser Joseph W | Sr VP & GM Trauma & Deformity | 2,554 0.0115% | $43.74 | $111,705 | -14.43% | |
| 2023-02-02 | Sale | Odle Gregory A | Executive Vice President | 1,195 0.0053% | $50.00 | $59,754 | -20.17% | |
| 2023-01-20 | Sale | Odle Gregory A | Executive Vice President | 80 0.0004% | $47.00 | $3,760 | -11.95% |
Total: 100
*Gray background shows transactions not older than one year
Insider Historical Profitability
10.74%
| Berry Bernie B III | director | 23481 0.0967% | $588,903.48 | 1 | 13 | +70.71% |
| Pelizzon David R | director | 23125 0.0952% | $579,975.00 | 5 | 0 | +31.39% |
| Ruf Harold | 13824 0.0569% | $346,705.92 | 3 | 0 | +18.58% | |
| Pritzker Jennifer N. | 10 percent owner | 707 0.0029% | $17,731.56 | 7 | 0 | <0.0001% |
KIDS Institutional Investors: Active Positions
| Increased Positions | 50 | +31.65% | 2M | +13.66% |
| Decreased Positions | 69 | -43.67% | 2M | -12.69% |
| New Positions | 15 | New | 831,714 | New |
| Sold Out Positions | 31 | Sold Out | 759,967 | Sold Out |
| Total Postitions | 139 | -12.03% | 16M | +0.98% |
KIDS Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Brown Capital Management Llc | $43,709.00 | 7.84% | 1.88M | -359,515 | -16.04% | 2024-12-31 |
| Brown Advisory Inc | $35,620.00 | 6.39% | 1.53M | -63,375 | -3.97% | 2024-12-31 |
| Blackrock, Inc. | $29,238.00 | 5.25% | 1.26M | -27,730 | -2.15% | 2024-12-31 |
| Braidwell Lp | $25,722.00 | 4.62% | 1.11M | 0 | 0% | 2024-12-31 |
| Wellington Management Group Llp | $24,643.00 | 4.42% | 1.06M | +178,078 | +20.16% | 2024-12-31 |
| Morgan Stanley | $23,041.00 | 4.14% | 992,299 | +357,956 | +56.43% | 2024-12-31 |
| Vanguard Group Inc | $21,453.00 | 3.85% | 923,890 | -32,165 | -3.36% | 2024-12-31 |
| Granahan Investment Management, Llc | $18,259.00 | 3.28% | 786,369 | -223,890 | -22.16% | 2024-12-31 |
| Wasatch Advisors Lp | $16,169.00 | 2.9% | 696,318 | +223,217 | +47.18% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $15,603.00 | 2.8% | 671,968 | +152,681 | +29.4% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.